The partners will evaluate new biomarkers that they both find, and will assess the possibility for a preterm birth prognostic panel.
The firm’s emphasis on automation has yielded Dx products for blood banks, assays for HIV and acute kidney injury, and flexible diagnostic test systems that can adapt to labs’ changing needs.
Invitae will test 1,000 breast cancer patients from TME practices using its hereditary cancer test, regardless of whether they meet current eligibility criteria.
ARUP said it is seeing larger volumes of pathology samples, requiring more advanced and efficient workflows.
Merck is hoping NanoString's multiplex platform can support gene expression signatures that will better predict which patients will respond to checkpoint inhibitors like its Keytruda.
T2 and Allergan will develop a novel diagnostic panel for the detection of Gram-negative bacterial species and antibiotic resistance in patients with bacterial infections.
"The idea is to open up a completely new market for bringing genetics into the lower-risk general population," Invitae CEO Randy Scott told GenomeWeb.
The lead investigators said that Foundation Medicine's NGS test will enable the beginning of targeted treatment within seven days of diagnosis.
Under the terms of the agreement, Q2 Solutions will develop companion diagnostics on Illumina's MiSeqDx instrument.
Under the partnership, Myriad will be ION's preferred partner for providing hereditary testing to its member practices.